Somewhat Favorable News Coverage Somewhat Unlikely to Impact Integra Lifesciences (IART) Share Price

Press coverage about Integra Lifesciences (NASDAQ:IART) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Integra Lifesciences earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the life sciences company an impact score of 46.3167379351658 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:

Shares of Integra Lifesciences (NASDAQ:IART) traded down $0.14 during midday trading on Tuesday, reaching $49.54. The company’s stock had a trading volume of 644,797 shares, compared to its average volume of 724,133. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39. The company has a market cap of $3,890.00, a PE ratio of 81.21, a PEG ratio of 1.55 and a beta of 0.65. Integra Lifesciences has a 1-year low of $40.51 and a 1-year high of $56.42.

Integra Lifesciences (NASDAQ:IART) last announced its earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.02). The company had revenue of $278.83 million for the quarter, compared to the consensus estimate of $286.00 million. Integra Lifesciences had a net margin of 4.52% and a return on equity of 16.35%. The firm’s revenue was up 11.4% compared to the same quarter last year. During the same period last year, the business posted $0.93 EPS. analysts forecast that Integra Lifesciences will post 1.85 EPS for the current year.

IART has been the topic of several research reports. Zacks Investment Research downgraded Integra Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Royal Bank of Canada restated a “sector perform” rating and set a $50.00 price objective (up from $48.00) on shares of Integra Lifesciences in a report on Thursday, November 9th. Oppenheimer set a $58.00 price objective on Integra Lifesciences and gave the stock a “buy” rating in a report on Tuesday, December 12th. Barclays restated an “equal weight” rating and set a $53.00 price objective (up from $47.00) on shares of Integra Lifesciences in a report on Tuesday, September 12th. Finally, Wells Fargo & Co downgraded Integra Lifesciences from an “outperform” rating to a “market perform” rating in a report on Sunday, October 29th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the company. Integra Lifesciences has an average rating of “Hold” and an average price target of $52.70.

In other Integra Lifesciences news, VP Richard D. Gorelick sold 1,500 shares of the stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total transaction of $70,785.00. Following the sale, the vice president now owns 21,665 shares of the company’s stock, valued at approximately $1,022,371.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Barbara B. Hill bought 10,768 shares of the company’s stock in a transaction on Tuesday, October 31st. The shares were bought at an average cost of $46.66 per share, for a total transaction of $502,434.88. Following the transaction, the director now directly owns 55,540 shares in the company, valued at approximately $2,591,496.40. The disclosure for this purchase can be found here. 21.50% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Integra Lifesciences (IART) Share Price” was published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.com-unik.info/2018/01/09/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-integra-lifesciences-iart-share-price.html.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Insider Buying and Selling by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit